皮肤鳞状细胞癌（cSCC）是一种常见的皮肤癌，但对晚期病例的治疗效果有限。滋养层细胞表面抗原2（TROP2）是一种广泛表达于多种肿瘤的细胞表面蛋白，对肿瘤细胞的生长、凋亡、迁移、侵袭和转移等关键过程产生重要影响。 Sacituzumab govitecan 是一种靶向 TROP2 的抗体药物偶联物 (ADC)，正在成为一种有前景的抗癌治疗策略。在这项研究中，我们研究了 51 名患者的 cSCC 组织中 TROP2 的表达，并评估了其在 A431 人 SCC 细胞系中的功能。免疫组织化学分析显示，cSCC 组织和 A431 细胞的质膜上有 TROP2 表达。 A431 细胞对 sacituzumab govitecan 表现出敏感性，活细胞数量呈显着的浓度依赖性下降。此外，TROP2 的敲低导致细胞周期蛋白 D1 和 BCL-2 的表达减少，以及细胞活力降低。 TROP2 的敲低还导致波形蛋白表达减少，以及迁移能力降低。这些发现表明 TROP2 在 cSCC 细胞增殖和迁移中发挥着至关重要的作用，并凸显了 sacituzumab govitecan 作为 cSCC 有前途的治疗选择的潜力。© 2024 作者。约翰·威利出版的《实验皮肤病学》

Cutaneous squamous cell carcinoma (cSCC) is a common form of skin cancer, but treatments for advanced cases have limited efficacy. Trophoblast cell-surface antigen 2 (TROP2) is a cell-surface protein that is widely expressed in various tumours, where it exerts significant influence over critical processes such as tumour cell growth, apoptosis, migration, invasion and metastasis. Sacituzumab govitecan, an antibody-drug conjugate (ADC) targeting TROP2, is emerging as a promising strategy for anticancer therapy. In this study, we investigated TROP2 expression in cSCC tissues from 51 patients and evaluated its function in the A431 human SCC cell line. Immunohistochemical analysis revealed TROP2 expression on the plasma membrane of cSCC tissues and A431 cells. A431 cells showed sensitivity to sacituzumab govitecan with a significant concentration-dependent decrease in viable cell number. In addition, Knockdown of TROP2 resulted in decreased expression of cyclin D1 and BCL-2, along with reduced cell viability. Knockdown of TROP2 also resulted in decreased expression of vimentin, along with reduced migratory capacity. These findings suggest that TROP2 plays a crucial role in cSCC cell proliferation and migration, and highlight the potential of sacituzumab govitecan as a promising therapeutic option for cSCC.© 2024 The Author(s). Experimental Dermatology published by John Wiley & Sons Ltd.